Phase 3 EU trial protocols flag potential liver safety risks for Bristol Myers Squibb’s admilparant in pulmonary fibrosis—see what it means for BMY.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results